Literature DB >> 8697042

Molecular biology of serotonin receptors.

M Baez1, J D Kursar, L A Helton, D B Wainscott, D L Nelson.   

Abstract

Over the last several years the use of molecular cloning technology has revealed a vast diversity among serotonin (5-HT) receptors, whereby what was previously thought to be a family of three pharmacologically defined classes of 5-HT receptors is actually composed of seven distinct subfamilies designated 5-HT1-7. The 5-HT1, 5-HT2, and 5-HT5 subfamilies currently consist of five, three and two subtypes respectively while the 5-HT3, 5-HT4, 5-HT6, and 5-HT7 "subfamilies" have at present one subtype each. Fourteen separate genes encode 13 receptors which fall in the superfamily of G protein-coupled receptors and one ligand-gated ion channel receptor. Our lab has contributed to the elucidation of this subtype diversity by cloning the cDNAs from both rat and human encoding the 5-HT2B receptor. This receptor subtype is equally homologous (approximately 70%) to the 5-HT2A and 5-HT2C receptors when amino acids comprising the transmembrane domains are compared and is clearly the third member of the 5-HT2 subfamily. The 5-HT2B receptor has been shown to couple to phosphoinositide hydrolysis as do the other two members of this subfamily when expressed in AV12-664 cells. Limited pharmacological analyses indicated that both rat and human 5-HT2B receptors are similar but distinguishable. With one tantalizing exception, the mRNAs for these receptors appear to be similarly distributed within rat and human. The 5-HT2B receptor mRNA is not found in rat brain, whereas in human brain it has been identified in multiple regions. This later finding suggests that the 5-HT2B receptor may be serving a unique CNS function in man that is absent in rat.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8697042     DOI: 10.1002/j.1550-8528.1995.tb00211.x

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  7 in total

1.  Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.

Authors:  E P Bouras; M Camilleri; D D Burton; S McKinzie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation.

Authors:  Baoman Li; Shiquen Zhang; Min Li; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

3.  Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia.

Authors:  Baoman Li; Lu Dong; Bing Wang; Liping Cai; Ning Jiang; Liang Peng
Journal:  Neurochem Res       Date:  2012-06-19       Impact factor: 3.996

4.  Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration.

Authors:  Ebenezer K C Kong; Liang Peng; Ye Chen; Albert C H Yu; Leif Hertz
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

5.  Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.

Authors:  Baoman Li; Shiquen Zhang; Hongyan Zhang; Weiwei Nu; Liping Cai; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2008-08-29       Impact factor: 4.530

Review 6.  Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.

Authors:  Leif Hertz; Douglas L Rothman; Baoman Li; Liang Peng
Journal:  Front Behav Neurosci       Date:  2015-02-20       Impact factor: 3.558

7.  A novel method for inducing nerve growth via modulation of host resting potential: gap junction-mediated and serotonergic signaling mechanisms.

Authors:  Douglas J Blackiston; George M Anderson; Nikita Rahman; Clara Bieck; Michael Levin
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.